Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pacira's Exparel Adds Nerve Block Indication For Shoulder Surgery In US

Executive Summary

In unusual move, labeling lists data supporting use as nerve block as well as other trials that 'do not support' a broader nerve block indication beyond brachial plexus; labeling includes data on reduced opioid use but notes clinical benefit has not been established.

Advertisement

Related Content

US FDA, Advisory Committees Rarely Disagree
Complete Response Letters See Uptick With US FDA's Thumbs Down For Waylivra
Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review
FDA’s Tactical Exparel Label May Suggest Broader Off-Label Strategy
Pacira’s Long Day With Exparel
Opioid-Sparing Claims Should Meet High Bar, US FDA Panel Says
Pacira's Exparel: US FDA Panel Narrowly Rejects Nerve Block Claim
FDA Makes Broad Concessions In Settling Pacira Promotion Suit

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122865

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel